BIO

256.76

8.73% -23.36

Handel nachbörslich: 280.12 23.36 +9.10%

Bio Rad Laboratories Inc (BIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$280.12

Offen:

$261.69

24-Stunden-Volumen:

939.88K

Relative Volume:

3.02

Marktkapitalisierung:

$6.93B

Einnahmen:

$2.58B

Nettoeinkommen (Verlust:

$759.90M

KGV:

9.1973

EPS:

27.9168

Netto-Cashflow:

$374.60M

1W Leistung:

-11.18%

1M Leistung:

-8.15%

6M Leistung:

-19.99%

1J Leistung:

+6.34%

1-Tages-Spanne:

$242.28

$264.22

1-Wochen-Bereich:

$242.28

$294.05

52-Wochen-Spanne:

$211.43

$343.12

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Firmenname

Bio Rad Laboratories Inc

Sektor

Healthcare (1118)

Branche

Medical Devices (142)

Telefon

(510) 724-7000

Adresse

1000 ALFRED NOBEL DRIVE, HERCULES

Mitarbeiter

7,450

Twitter

@BioRadLifeSci

Nächster Verdiensttermin

2026-04-30

Neueste SEC-Einreichungen

BIO's Discussions on Twitter

Compare BIO vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BIO Bio Rad Laboratories Inc	256.76	7.54B	2.58B	759.90M	374.60M	27.92
ABT Abbott Laboratories	89.47	163.10B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	294.69	123.10B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	80.00	105.15B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	56.51	86.87B	20.62B	3.56B	3.66B	2.3847
EW Edwards Lifesciences Corp	83.99	47.44B	6.30B	1.07B	1.34B	1.8406

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-07	Herabstufung	Citigroup	Buy → Neutral
2024-10-01	Hochstufung	Citigroup	Neutral → Buy
2024-08-28	Eingeleitet	Wells Fargo	Equal Weight
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-04-03	Herabstufung	Citigroup	Buy → Neutral
2023-12-07	Eingeleitet	UBS	Buy
2023-06-16	Eingeleitet	Wells Fargo	Overweight
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-01-28	Bestätigt	Citigroup	Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2018-10-17	Eingeleitet	Goldman	Buy
2018-09-20	Eingeleitet	Morgan Stanley	Equal-Weight
2018-02-16	Herabstufung	CL King	Buy → Neutral
2017-07-13	Eingeleitet	Wells Fargo	Outperform
2017-06-28	Hochstufung	Deutsche Bank	Hold → Buy
2017-01-18	Eingeleitet	Deutsche Bank	Hold
2016-10-13	Eingeleitet	CL King	Buy
2015-05-06	Bestätigt	Jefferies	Buy
2009-12-18	Eingeleitet	Maxim Group	Buy
2009-11-06	Eingeleitet	Jefferies & Co	Buy
2009-07-17	Eingeleitet	Soleil	Buy
2007-09-26	Eingeleitet	Banc of America Sec	Buy
2007-02-23	Herabstufung	Robert W. Baird	Outperform → Neutral

Alle ansehen

Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten

04:11 AM

Bio-Rad Laboratories stock falls on lowered revenue outlook By Investing.com - Investing.com Canada

04:11 AM

01:38 AM

Bio-Rad drops 10.2% as guidance cut and Sartorius valuation hit overshadow Q1 results - Quiver Quantitative

01:38 AM

01:11 AM

Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga

01:11 AM

12:15 PM

Why Bio-Rad Laboratories Is Plunging 10.8%: Wells Fargo Maintains Equal-Weight - AlphaStreet

12:15 PM

10:35 AM

Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price - MarketBeat

10:35 AM

10:29 AM

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings - MarketBeat

10:29 AM

08:30 AM

Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

08:30 AM

07:27 AM

Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN

07:27 AM

05:41 AM

Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat

05:41 AM

03:57 AM